What to Know About Relapsed Disease Treatment After 12 Months in DLBCL

In a previous episode, “The Fellow on Call” hosts Ronak Mistry, DO; Vivek Patel, MD; and Dan Hausrath, MD; focused their episode on primary refractory diffuse large B-cell lymphoma (DLBCL). Now, they’re back with part one of a two-part discussion surrounding relapsed DLBCL.

The episode talks about how to approach relapsed disease after 12 months, how to approach relapse with central nervous system (CNS) involvement, the role of chimeric antigen receptor (CAR)-T therapy versus autologous transplant in this setting, and how to approach treatment in patients who are poor candidates for autologous CAR-T.

This podcast originally appeared on thefellowoncall.com.